May 6, 2024 Non Regulatory InDex Pharmaceuticals provides a status update and informs about Extraordinary General Meeting on June 10, 2024 Read more
February 26, 2024 Non Regulatory InDex Pharmaceuticals provides an update on company’s future Read more
October 30, 2023 Non Regulatory InDex Pharmaceuticals Holding AB (publ) announces Nomination Committee for the 2024 Annual General Meeting Read more
October 20, 2023 Non Regulatory InDex Pharmaceuticals has been granted a new patent for cobitolimod in South Korea Read more
October 11, 2023 Non Regulatory InDex Pharmaceuticals announces that all patients needed for the cobitolimod dose selection milestone have completed Induction Study 1 of the phase III program CONCLUDE Read more
August 22, 2023 Non Regulatory ”Positive results from PK study with cobitolimod” selected as one of the best abstracts for poster presentation at UEGW Read more
April 26, 2023 Non Regulatory Welcome to an InDex Pharmaceuticals business update presentation in Stockholm on May 9, from 13:00 to 15.30 CET Read more
March 15, 2023 Non Regulatory InDex Pharmaceuticals announces positive results from a pharmacokinetic (PK) study with cobitolimod Read more
February 14, 2023 Non Regulatory InDex Pharmaceuticals provides complementary information on the phase III program CONCLUDE with cobitolimod Read more
October 26, 2022 Non Regulatory InDex Pharmaceuticals Holding AB (publ) announces Nomination Committee for the 2023 Annual General Meeting Read more
October 5, 2022 Non Regulatory InDex Pharmaceuticals to exhibit at United European Gastroenterology Week Read more
August 16, 2022 Non Regulatory InDex Pharmaceuticals announces successful interactions with the PMDA for the clinical development of cobitolimod in Japan Read more
March 7, 2022 Non Regulatory Reminder: InDex Pharmaceuticals hosts Capital Markets Day on March 14, 2022 Read more
February 15, 2022 Non Regulatory Invitation to InDex Pharmaceuticals’ Capital Markets Day on March 14, 2022 Read more
December 8, 2021 Non Regulatory InDex Pharmaceuticals enrols first patient in the PK study with cobitolimod Read more
November 10, 2021 Non Regulatory InDex Pharmaceuticals Holding AB (publ) announces Nomination Committee for the 2022 Annual General Meeting Read more
November 8, 2021 Non Regulatory InDex Pharmaceuticals presents at Redeye Life Science Day 2021 Read more
August 23, 2021 Non Regulatory InDex Pharmaceuticals strengthens the clinical development organization in preparation of the start of the phase III study CONCLUDE with cobitolimod Read more
April 7, 2021 Non Regulatory InDex Pharmaceuticals gets patent for additional DIMS compounds granted in Europe Read more
March 30, 2021 Non Regulatory InDex Pharmaceuticals enters agreement with Parexel Biotech for phase III clinical study of cobitolimod for ulcerative colitis Read more
March 15, 2021 Non Regulatory InDex Pharmaceuticals Holding AB (publ) announces changes in the Nomination Committee for the 2021 Annual General Meeting Read more
March 10, 2021 Non Regulatory InDex Pharmaceuticals presents at Barclays Global Healthcare Conference and Carnegie Nordic Virtual Healthcare Seminar Read more
December 3, 2020 Non Regulatory InDex Pharmaceuticals Holding AB (publ) announces Nomination Committee for the 2021 Annual General Meeting Read more
November 26, 2020 Non Regulatory InDex Pharmaceuticals to host virtual R&D day on December 8, 2020 Read more
November 24, 2020 Non Regulatory InDex Pharmaceuticals presents at Redeye Life Science Day 2020 Read more
October 6, 2020 Non Regulatory The Lancet Gastroenterology and Hepatology publishes InDex Pharmaceuticals’ results of the phase IIb study with cobitolimod Read more
August 24, 2020 Non Regulatory InDex Pharmaceuticals to present the successful results of the CONDUCT study at two leading medical conferences Read more
April 8, 2020 Non Regulatory Update on InDex Pharmaceuticals Holding AB’s (InDex) Annual General Meeting addressing covid-19 Read more
March 31, 2020 Non Regulatory InDex Pharmaceuticals receives grant from Vinnova for pre-clinical development of DIMS compounds in inflammation Read more
February 25, 2020 Non Regulatory InDex Pharmaceuticals publishes mechanism of action data for cobitolimod in scientific journal Read more
November 18, 2019 Non Regulatory InDex Pharmaceuticals presents at Redeye Life Science Day and Avanza Börsdag November 19, 2019 Read more
November 1, 2019 Non Regulatory InDex Pharmaceuticals Holding AB (publ) announces Nomination Committee for the 2020 Annual General Meeting Read more
October 24, 2019 Non Regulatory InDex Pharmaceuticals presents today at Redeye Investor After Work Read more
June 3, 2019 Non Regulatory InDex Pharmaceuticals presents at Redeye Growth Day on June 10, 2019 Read more
November 6, 2018 Non Regulatory InDex Pharmaceuticals Holding AB (publ) announces Nomination Committee for the 2019 Annual General Meeting Read more
October 19, 2018 Non Regulatory InDex Pharmaceuticals publishes post-hoc analysis of the COLLECT study Read more
May 31, 2018 Non Regulatory InDex Pharmaceuticals will participate in the Digestive Disease Week (DDW) Read more
April 12, 2018 Non Regulatory InDex Pharmaceuticals announces the agenda for its Capital Markets Day in Stockholm on April 25, 2018 Read more
March 26, 2018 Non Regulatory Save the date: InDex Pharmaceuticals to host Capital Markets Day in Stockholm on April 25, 2018 Read more
February 13, 2018 Non Regulatory InDex Pharmaceuticals presents mechanism of action data for cobitolimod at the ECCO congress Read more
November 16, 2017 Non Regulatory InDex Pharmaceuticals Holding AB (publ) announces Nomination Committee and financial reporting dates for 2018 Read more
October 26, 2017 Non Regulatory InDex Pharmaceuticals will participate in the United European Gastroenterology Week (UEGW) Read more
August 9, 2017 Non Regulatory InDex Pharmaceuticals receives orphan-drug designation for pediatric ulcerative colitis in the US Read more
May 5, 2017 Non Regulatory InDex Pharmaceuticals will participate in the Digestive Disease Week (DDW) Read more
March 22, 2017 Non Regulatory InDex Pharmaceuticals concludes well attended Investigators’ Meeting for the phase IIb study CONDUCT Read more
January 23, 2017 Non Regulatory InDex Pharmaceuticals will participate in the European Crohn’s and Colitis Organisation (ECCO) Congress Read more
October 18, 2016 Non Regulatory Results from InDex Pharmaceuticals’ COLLECT study well received at UEGW Read more
October 10, 2016 Non Regulatory InDex Pharmaceuticals presents results from the COLLECT study at the United European Gastroenterology Week 2016 Read more
September 30, 2016 Non Regulatory InDex Pharmaceuticals announces the outcome of its initial public offering in connection with planned listing on Nasdaq First North Stockholm Read more
September 26, 2016 Non Regulatory InDex Pharmaceuticals ends the subscription period for the initial public offering in connection with listing on Nasdaq First North Tuesday, September 27 Read more
September 14, 2016 Non Regulatory InDex Pharmaceuticals initiates the subscription period for the initial public offering in connection with planned listing on Nasdaq First North Read more
September 13, 2016 Non Regulatory InDex Pharmaceuticals publishes prospectus regarding initial public offering in connection with planned listing on Nasdaq First North Stockholm Read more
September 13, 2016 Non Regulatory InDex Pharmaceuticals conducts initial public offering in connection with planned listing on Nasdaq First North Stockholm Read more
August 25, 2016 Non Regulatory InDex Pharmaceuticals Holding AB – Interim Report 27 June – 30 June 2016 Read more
August 15, 2016 Non Regulatory InDex Pharmaceuticals AB – Interim Report January – June 2016 Read more
May 23, 2016 Non Regulatory InDex Pharmaceuticals receives grant from Sweden´s innovation agency Vinnova for pre-clinical development of DIMS compounds in inflammation Read more
March 7, 2016 Non Regulatory InDex Pharmaceuticals Receives FDA Clearance of IND for Cobitolimod (Kappaproct®) Phase IIb Trial Read more
February 10, 2016 Non Regulatory InDex Pharmaceuticals receives approval of the International Nonproprietary Name (INN) cobitolimod for their lead drug candidate Kappaproct® Read more
August 20, 2015 Non Regulatory InDex Pharmaceuticals AB – Interim Report January – June 2015 Read more
July 9, 2015 Non Regulatory InDex Pharmaceuticals appoints Uli Hacksell and Jesper Wiklund to its Board of Directors Read more
June 30, 2015 Non Regulatory InDex Pharmaceuticals regains European rights to Kappaproct® in ulcerative colitis Read more
February 3, 2015 Non Regulatory InDex Pharmaceuticals to present results from the COLLECT trial at the 10th Congress of the European Crohn’s and Colitis Organisation Read more
June 27, 2014 Non Regulatory InDex Pharmaceuticals announces results from COLLECT, a clinical trial of Kappaproct® in the treatment of moderate to severe Ulcerative Colitis Read more
April 1, 2014 Non Regulatory InDex Pharmaceuticals and Almirall enter into a license agreement for European rights of the phase III drug candidate Kappaproct Read more
February 25, 2014 Non Regulatory InDex Pharmaceuticals closes $20 m financing round and welcomes NeoMed as new shareholder Read more
April 8, 2013 Non Regulatory InDex Pharmaceuticals reports completion of patient recruitment in Phase III Ulcerative Colitis Study (COLLECT) with Kappaproct Read more
October 24, 2012 Non Regulatory InDex Pharmaceuticals Granted Japanese Patent for Novel Treatment of Steroid-Resistant Inflammation Read more
August 30, 2012 Non Regulatory InDex Pharmaceuticals Strengthens IP Position for Kappaproct Read more
July 9, 2012 Non Regulatory InDex publish positive results from Kappaproct Compassionate Use program Read more
June 19, 2012 Non Regulatory Kappaproct Drastically Reduces the Need for Colectomy in Patients with Severe Ulcerative Colitis Read more
May 29, 2012 Non Regulatory InDex Pharmaceuticals Appoints Stig Løkke Pedersen as Board Member Read more
April 26, 2012 Non Regulatory InDex Pharmaceuticals Granted US Patent for Novel Treatment of Steroid-Resistant Inflammation Read more
March 20, 2012 Non Regulatory InDex Pharmaceuticals develops companion diagnostic test for new ulcerative colitis therapy. Read more
March 6, 2012 Non Regulatory InDex Pharmaceuticals Starts Phase III COLLECT Study with Kappaproct Read more
October 24, 2011 Non Regulatory InDex Pharmaceuticals participates at the UEGW (19th United European Gastroenterology Week) at Stockholmsmässan Oct 24-26. Read more
July 7, 2011 Non Regulatory InDex Pharmaceuticals names Jesper Wiklund Chief Executive Officer Read more
May 17, 2011 Non Regulatory InDex Pharmaceuticals participates in the Swedish Congress Svenska Gastrodagarna in Umeå May 17-20, 2011. Read more
January 21, 2011 Non Regulatory Industrifonden new major shareholder in InDex Pharmaceuticals Read more
May 17, 2010 Non Regulatory Index Pharmaceuticals is present with a booth in the yearly congress Svenska Gatrodagarna in Stockholm 17-20 May, 2010 Read more
December 8, 2009 Non Regulatory Stockholms läns landsting introduces diagnostic test for patients with inflammatory bowel disease Read more
May 18, 2009 Non Regulatory Based on Positive Phase II Results InDex Pharmaceuticals Terminates Kappaproct Study in Advance Read more